secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001237831-25-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical Q3 revenue $769M (+23% YoY); raises FY2025 EPS guidance to $3.75-$3.85
--------------------------------------------------------------------------------

- Net sales $769.0M, +22.9% YoY; base business (ex-Nevro) $669.8M (+7.0%); Nevro contributed $99.3M.
- GAAP diluted EPS $0.88, up 134% YoY; non-GAAP diluted EPS $1.18, up 42.6% YoY.
- FY2025 revenue guidance raised to $2.86-$2.90B; non-GAAP EPS raised to $3.75-$3.85 (prev $3.00-$3.30).
- Record non-GAAP free cash flow of $213.9M in Q3; share repurchases of $40M in Q3, total $255.5M YTD.
- Nevro acquisition now expected to be accretive to earnings in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000123783125000029/0001237831-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000123783125000029/gmed-20251106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001237831-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer